Dynavax Reaffirms Full Year 2024 Financial Guidance; Expects Cash & Equivalents To Be Higher Y/Y At December 31, 2024
Dynavax Reaffirms Full Year 2024 Financial Guidance; Expects Cash & Equivalents To Be Higher Y/Y At December 31, 2024
戴納瓦克斯重申2024年全年財務指導;預計截至2024年12月31日,現金及等價物將同比增長
- HEPLISAV-B net product revenue between approximately $265 - $280 million, including approximately $3 million in ex-U.S. sales through commercialization partnership in Germany
- HEPLISAV-B gross margin of approximately 80%
- HEPLISAV-B的淨產品收入約在2.65億美元至2.8億美元之間,其中包括通過德國商業化合作夥伴關係在美國以外的約300萬美元銷售額
- HEPLISAV-B 毛利率約爲 80%
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。